公开(公告)号：US20200054736A1

公开(公告)日：2020-02-20

申请号：US16342426

申请日：2017-10-19

申请人： John C. WILLIAMS ,  Christine BROWN ,  CITY OF HOPE

发明人： John C. WILLIAMS ,  Christine BROWN ,  Don J. DIAMOND

IPC分类号： A61K39/245 ,  C07K14/725 ,  A61K35/17 ,  A61P35/00 ,  C07K16/18 ,  C07K14/03

摘要： Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein). The engineered T cells provided herein may be used in combination with a viral vaccine (e.g. cytomegalovirus (CMV) Triplex Vaccine) to treat a variety of cancers. The methods described herein also permit in viva expansion of CMV-specific CAR T cells, instead of or in addition to ex vivo expansion, avoiding excessive T cell exhaustion that results in some cases from ex vivo manufacturing.

公开(公告)号：US20210061879A1

公开(公告)日：2021-03-04

申请号：US16958614

申请日：2018-12-31

申请人： CITY OF HOPE

发明人： John C. WILLIAMS ,  Christine BROWN ,  Kurt JENKINS ,  Yi-Chiu KUO ,  Cheng-Fu KUO

IPC分类号： C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N15/86

摘要： Provided herein are compositions which exhibit novel therapeutic capabilities and allow to reduce the off-target effect of therapeutic antibodies. The compositions include recombinant proteins that if expressed by a T cell can efficiently recruit therapeutic antibodies to their site of action.

公开(公告)号：US20220354852A1

公开(公告)日：2022-11-10

申请号：US17662629

申请日：2022-05-09

申请人： CITY OF HOPE

发明人： Margarita GUTOVA ,  Michael KAHN ,  Christine BROWN

IPC分类号： A61K31/519 ,  A61P35/00 ,  A61K35/17 ,  A61K38/17 ,  A61K31/675

摘要： This disclosure relates to cells that express a chimeric antigen receptor that targets IL13Rα2 and/or HER2 and methods for treating a brain tumor by administering a population of cells expressing a chimeric antigen receptor that targets IL13Rα2 and/or HER2 in combination with a Wnt/β-catenin pathway modulator to a subject having a brain tumor.

公开(公告)号：US20220062410A1

公开(公告)日：2022-03-03

申请号：US17465728

申请日：2021-09-02

申请人： CITY OF HOPE

发明人： John C. WILLIAMS ,  Christine BROWN ,  Don J. DIAMOND

IPC分类号： A61K39/245 ,  A61P35/00 ,  A61K35/17 ,  C07K14/03 ,  C07K14/725 ,  C07K16/18

摘要： Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein). The engineered T cells provided herein may be used in combination with a viral vaccine (e.g. cytomegalovirus (CMV) Triplex Vaccine) to treat a variety of cancers. The methods described herein also permit in vivo expansion of CMV-specific CAR T cells, instead of or in addition to ex vivo expansion, avoiding excessive T cell exhaustion that results in some cases from ex vivo manufacturing.